The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council

Authors
Publication date
30 March 2023
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Ezid

    redirect
    oaiark:/13030/qt1q04z8s1
    Last time updated on 13/12/2023